Cerebral revascularization: surgical and endovascular approaches …

Stroke & Vascular Disorders

Updated 06.05.2024
Released 12.05.2001
Expires For CME 06.05.2027

Cerebral revascularization: surgical and endovascular approaches

Authors: Pui Man Rosalind Lai MD, Tanya Singh MD

See Contributor Disclosures

Editor: Steven R Levine MD

Cerebral revascularization: surgical and endovascular approaches

In This Article

Quick Link

Introduction

Overview

Cerebrovascular insufficiency, typically caused by extra- or intracranial steno-occlusive disease, remains the leading cause of ischemic stroke. The management of various types of stenosis varies according to the chronicity and symptomatic presentation of the patient. Mechanical thrombectomy has emerged as the standard of care for treating acute occlusions of the carotid or large intracranial vessels. For chronic extracranial occlusion, surgical options can range from carotid endarterectomy to transfemoral or transcarotid stent placement. Intracranial steno-occlusive disease due to intracranial atherosclerosis is often addressed through antiplatelet therapy. Surgical interventions are reserved for cases where initial medical management proves ineffective. These options may include extracranial-to-intracranial (EC-IC) bypass and endovascular angioplasty with or without intracranial vessel stenting. This updated article delves into the etiologies of various cerebrovascular insufficiencies and provides insights into surgical options and techniques.

Key points

	• Cerebrovascular insufficiency is a leading cause of ischemic stroke.
	• Management of cerebrovascular insufficiency depends on the chronicity and symptomatology of the patient.
	• Mechanical thrombectomy has become the standard of care for acute carotid and intracranial large artery occlusion.
	• Chronic or asymptomatic cerebrovascular insufficiency may be managed medically, but symptomatic lesions or lesions refractory to medical management may require surgical or endovascular revascularization.

Historical note and terminology

Descriptions of early attempts at surgical embolectomy for the treatment of brain ischemia appeared in the literature in the 1950s (117; 27). Microsurgical reconstruction of brain arteries, ie, cerebral bypass surgery, became available following the introduction of the operating microscope in the 1960s (122). Indications for intracranial revascularization procedures have subsequently been refined, and surgical techniques have considerably evolved over the following decades.

The association between extracranial carotid pathology and ipsilateral ischemic stroke was recognized in the early 1900s (24; 66), and carotid endarterectomy for stroke prevention was introduced only in the second half of the 20th century (38; 48). There was an exponential growth in the application of carotid endarterectomy for treating carotid atherosclerotic disease, with more than 30,000 carotid endarterectomies being carried out annually in the United States by the 1980s.

Endovascular cerebral revascularization began with the introduction of percutaneous dilating angioplasty in the 1960s (41). A decade later, percutaneous transluminal angioplasty was adopted (57). Carotid artery stenting became available in the mid-1990s (40). Stents have since been used in nearly every segment of the cerebral circulation and for various indications.

Intraarterial installation of thrombolytic drugs directly into the occluding thrombus for the urgent revascularization of patients suffering from cerebral artery occlusions became available in the 1980s (125; 126). However, intra-arterial thrombolysis remained limited by its comparatively low ability to re-establish flow, which contributed to the development of endovascular mechanical thrombectomy. Initially, the occluding particle was retrieved using various types of snares. However, snares were technically challenging to use and were, therefore, progressively replaced by more trackable and more efficient devices, so-called stent retrievers (49). Although first-generation stent retrievers allowed an increase in recanalization rates, their ability to improve functional outcomes in patients suffering from large cerebral artery occlusions remains unproven (109; 14; 15). The turning point for mechanical thrombectomy occurred in 2015 when five multicenter, open-label randomized controlled trials (MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, and REVASCAT) unequivocally demonstrated that mechanical thrombectomy with second-generation stent retriever devices was superior to standard treatment with intravenous thrombolysis alone for large-vessel, anterior circulation occlusions (10; 18; 53; 70; 104). Since then, indications for mechanical thrombectomy have continued to expand, and clot retrieval techniques, as well as devices, continue to be refined.

Clinical manifestations

General concepts. Atherosclerosis is the primary cause of cerebrovascular insufficiency. Nonatherosclerotic etiologies include various types of inflammatory disease as well as trauma. Generally, any lesion capable of producing cerebrovascular insufficiency, with or without ischemia or infarction, does so by a combination of distinct attributes, each with its own pathogenic implications (Table 1).

Table 1. Attributes That Determine the Risk Of Arterial Lesions To Induce Cerebral Ischemia

Attribute	Defining criterion	Influencing variables
Hemodynamic impact	Degree of bulk flow alteration downstream from the lesion	Degree of stenosis Length of stenotic segment Collateral flow patterns Cerebrovascular reserve Plaque instability
Emboligenicity	Propensity of the lesion to generate thromboembolism	Endothelial integrity Surface irregularities Lesion instability Lesion morphology Intraplaque hemorrhage Degree of flow reduction
Branch involvement	Involvement of arterial branches by the lesion, through extension or embedment	Competing target tissues

Hemodynamic impact. The hemodynamic impact of a stenotic lesion depends on the reduction of bulk flow in the affected artery and, consequently, the reduction of perfusion in its vascular bed. From a clinical point of view, the patient may remain asymptomatic, may suffer from hypoperfusion symptoms, or may develop ischemic stroke. The appearance of clinical manifestations depends on factors such as metabolic needs of the concerned territory or competence of collateral circulation.

The flow of fluids through a tubular entity such as a cerebral artery can be approximated by Poiseuille’s Law, which states that the flow depends on the viscosity of the fluid, the pressure gradient along the tube, the length of the tube, and the diameter of the tube. It is important to remember the strong impact of caliber variations, meaning, for instance, that reducing the tube’s diameter by half (50% stenosis) decreases the flow rate by 16-fold (r4). Quantifying bulk arterial flow with sufficient accuracy for clinical application is challenging despite the introduction of techniques like quantitative magnetic resonance angiography (35). Novel imaging techniques, such as 4D flow MR imaging, are being developed to evaluate flow patterns and circulation but are not routinely used in clinical practice. Therefore, surrogate measurements, such as “degree of stenosis” (ie, the maximal reduction in vascular cross-sectional diameter caused by a lesion, typically expressed as a percentage), are used in clinical practice to estimate the severity of a stenotic lesion and to determine whether or not a revascularization procedure is indicated.

Perfusion imaging is now used routinely to evaluate for occlusive lesions as a surrogate for adequate blood flow to areas of the brain. The hemodynamic impact of a stenotic cerebrovascular lesion (as well as the effects of revascularization) can be estimated quantitatively or semi-quantitatively by a range of advanced imaging techniques that include computed tomography perfusion imaging, magnetic resonance perfusion imaging, and positron emission tomography (121; 78; 23).

Emboligenicity. Stenotic lesions can also produce downstream ischemia by embolus formation. This phenomenon can occur even at non-flow-limiting degrees of stenosis. From a clinical point of view, the patient may remain asymptomatic (“silent emboli” but with radiographic evidence) or develop neurologic impairment, depending on the location and size of the thromboembolic stroke.

As the vessel lumen decreases, there is a shift from laminar to turbulent flow. Turbulent flow is associated with disturbed hemostasis caused by increased platelet aggregation (ie, "white clot" formation), resulting in thromboemboli formation. As flow compromise progresses, turbulence intensifies, and downstream perfusion is reduced. This adds another dimension to the disturbance of hemostasis, hence, the risk for stroke: sluggish flow as a prethrombotic state (ie, "red clot" formation). Finally, occlusion is followed by the appearance of a stagnant column of flow distal to the lesion, with its consequent downstream hemodynamic compromise.

The propensity of a stenotic lesion to generate thromboembolism also depends on its endothelial surface integrity, morphology (ie, composition), and stability. Lesions with a smooth surface and endothelial integrity have comparatively little emboligenic potential. Disruption of endothelial continuity results in exposure of the subendothelial thrombogenic surfaces, thereby, increasing the likelihood of thromboembolism. The major sources of emboli are secondary to carotid stenosis or from cardiac origin.

Branch involvement. Cerebrovascular lesions often involve branching arterial segments. Carotid artery stenosis and occlusion typically occur at or immediately distal to the carotid bifurcation. It is critical to evaluate all branching arteries for treatment decision-making. In certain arterial segments, occlusion of certain branching arteries (eg, external carotid artery) is of no clinical consequence and generally well tolerated, whereas occlusion of other branching arteries (eg, middle cerebral artery or anterior cerebral artery) is critical. Similarly, collateral branches embedded into the lesion itself represent a challenge from diagnostic and therapeutic points of view.

Extracranial atherosclerotic diseases

Carotid stenosis

Extracranial carotid atherosclerosis accounts for up to 15% of ischemic strokes in the United States (47). The disease is more prevalent in men, and its prevalence steadily increases with age (44; 37). The management of extracranial carotid atherosclerosis depends on a combination of factors that include the symptomatic nature of the patient, the anatomy of the carotid, and the patient’s comorbidities. Treatment options include maximal medical therapy, carotid endarterectomy, and peripheral or transcarotid stent placement with or without balloon angioplasty. Although carotid endarterectomy remains a standard of care for treating carotid stenosis, research has demonstrated equipoise, efficacy, and safety of carotid artery stenting in carefully selected patients. Currently, the Society for Vascular Surgery guidelines recommend carotid revascularization for symptomatic patients with recent stroke and greater than 50% stenosis and for asymptomatic patients with stenosis of 70% to 99% (02).

Symptomatic carotid stenosis. NASCET remains the most important North American trial to guide decision-making (93). When the trial was terminated during interim analysis, 659 symptomatic patients with more than 70% stenosis had been randomized to either a combination of medial management and carotid endarterectomy or to medical management alone. With 24 months of mean follow-up, ipsilateral strokes had occurred in 26% of the nonsurgical cohort, compared to 9% of patients who had undergone carotid endarterectomy. Patients who underwent carotid endarterectomy had a lower occurrence of stroke in any territory and major stroke or death from any cause, with perioperative morbidity and mortality of under 6%. Subsequent meta-analyses of major symptomatic carotid stenosis trials (NASCET, ECST, and Veterans Affairs Cooperative Studies Program Trial) demonstrated marginal stroke prevention benefit of carotid endarterectomy for patients with 50% to 69% stenosis, equivalent outcomes compared to medical management for patients with mild stenosis (30% to 49%), and worse outcomes with surgery for patients with minimal stenosis (less than 30%) (93; 84; 08; 101).

Asymptomatic carotid stenosis. In the ACAS and the ACST trials, asymptomatic patients with more than 60% carotid stenosis were randomized either to medical management combined with carotid endarterectomy or to medical management alone (07; 62). The ACAS investigators found a 5.9% absolute risk reduction in patients undergoing carotid endarterectomy (11% vs. 5.1%), and the ACST investigators similarly found a 5.4% absolute risk reduction in patients treated by carotid endarterectomy (11.8% vs. 6.4%). Of note, the benefits of surgery over medical management depend on a combined morbidity and mortality rate below 3% for carotid endarterectomy.

Treatment options for carotid artery stenosis.

Medical management. With the advent of statins, aggressive dyslipidemia treatment, and modern antiplatelet agents, there is ongoing debate about whether the results of these pivotal trials remain valid. CREST-2 is currently enrolling asymptomatic patients with more than 70% stenosis to separately compare carotid endarterectomy to modern medical management alone and carotid artery balloon-dilatation in combination with stent placement to modern medical management alone (estimated study completion, February 2026) (65).

Carotid endarterectomy. Carotid endarterectomy remains a valid standard of care for managing carotid artery stenosis. This procedure involves making a surgical incision, identifying the carotid artery, and removing the plaque, thereby restoring normal blood flow. This procedure may be performed under general anesthesia or local anesthesia. Carotid endarterectomy is beneficial for patients with low surgical risks, favorable surgical anatomy, and those who may not tolerate antiplatelets.

Peripheral (transfemoral or transradial) carotid artery stenting. Carotid artery stenting has emerged as an alternative revascularization technique for carotid artery stenosis. This endovascular approach involves inserting a catheter into the radial artery or the femoral artery and placing a self-expanding stent at the stenotic segment.

The CREST investigators demonstrated that carotid artery angioplasty with stent placement is at least equally effective as carotid endarterectomy, except in patients 70 years of age or older, who had a lower incidence of perioperative strokes with carotid endarterectomy when compared to angioplasty with stent placement (16).

Carotid artery angioplasty with stent placement carried a perioperative stroke and death rate of 7% to 9% in early experience. However, following the introduction of embolic protection devices, registries and clinical trials demonstrated a progressive decline in complication rates (60; 29), which paved the way to a more rigorous comparison of carotid artery angioplasty with stent placement and carotid endarterectomy (16; 11; 69; 103).

Carotid artery stenting: decreasing trend in major adverse cardiovascular events

The 30-day major adverse cardiovascular event rates reported by the various registries and studies of carotid artery stenting, organized chronologically by the year of publication, illustrate the continued decremental trend obs...

The pivotal studies, including CREST, demonstrated clinical equipoise between carotid artery angioplasty with stent placement and carotid endarterectomy in symptomatic patients, both in the short and long term (ie, 10-year follow-up) (16; 17). Additionally, these trials suggested that:

	1. Carotid endarterectomy is more likely to be complicated by myocardial infarction, whereas carotid artery angioplasty with stent placement has a higher risk for perioperative stroke.
	2. Carotid artery stenting has possibly a greater benefit in younger patients, whereas carotid endarterectomy is probably superior in patients older than 70 years.
	3. Carotid endarterectomy may be associated with fewer complications than carotid artery angioplasty with stent placement in women.
	4. Cranial nerve palsies were 15 times more frequent in patients undergoing carotid endarterectomy (ie, 4.7%).
	5. Maximal medical therapy can be aggressively implemented, leading to a significant reduction in risk factors.
	6. Early revascularization, either surgically or endovascularly, is not associated with increased risk of complications.
	7. There is no difference in cost between carotid endarterectomy and angioplasty with stent placement.

Surgical or endovascular treatment of asymptomatic patients remains controversial. CREST-2 is an ongoing trial to determine the benefits of endovascular and surgical management for asymptomatic patients.

Transcarotid artery revascularization. This newer procedure combines percutaneous common carotid artery puncture, proximal reverse flow embolic protection, and balloon dilatation with stent placement. Conceptually, this strategy addresses several key shortcomings of both endovascular and surgical carotid revascularization. In the absence of randomized trials, there have been promising initial results with this technique, for instance, regarding the reduction of the 1-year risk for ipsilateral stroke and death (75; 71). Transcarotid artery revascularization was initially approved for treating carotid artery stenosis with high physiologic or anatomic risks but has rapidly been adopted in the United States. In 2022, the US Food and Drug Administration expanded the indications for transcarotid artery revascularization to include patients with standard risk profiles.

Carotid artery stenting basics

(a) A high-grade internal carotid artery stenosis is identified angiographically. (b) The guide catheter has been advanced with its tip immediately proximal to the lesion, and a distal embolic protection device has been deploye...

Practice guidelines for extracranial circulation (carotid artery disease). The Society for Vascular Surgery clinical practice guidelines published in 2022 recommend carotid endarterectomy as the first-line treatment for patients with symptomatic carotid stenosis of 50% to 99% and for patients with asymptomatic carotid stenosis of 70% to 99% (02).

For patients with symptomatic carotid artery disease with greater than 50% stenosis and with stable stroke, carotid revascularization should be considered as soon as the patient is neurologically stable, after 48 hours from symptom onset and within 14 days from symptom onset.

Screening for asymptomatic carotid artery stenosis in patients without symptoms or risk factors for carotid artery disease is not recommended. In selected patients with asymptomatic carotid artery disease and increased risk factors, screening can be considered if the patient is a candidate for carotid intervention on the discovery of stenosis.

Nonatherosclerotic lesions

Regarding nonatherosclerotic lesions, such as traumatic injuries (eg, dissections), congenital vasculopathies (eg, fibromuscular dysplasia), and proliferative stenoses (eg, radiation), there remains a lack of large prospective clinical trials. A systematic review regarding the use of stents in many of these conditions suggests that complication rates may be favorable when medical therapy has failed but perhaps not in the case of primary stenting (12). Therefore, it seems reasonable to have an individualized therapeutic strategy for these patients as it remains difficult to make general recommendations.

Extracranial vertebrobasilar circulation

Vertebral pathology causing brain ischemia is associated with a 90-day risk of stroke of 25% to 30% following any index event (90; 58; 59), and approximately 15% to 50% of patients who present with vertebrobasilar insufficiency have either an underlying hemodynamically significant lesion or artery-to-artery embolisms (19). Treatment options for vertebrobasilar insufficiency have not been studied as extensively as those for carotid artery stenosis. In general, these lesions are often challenging to access by means of open surgery; therefore, endovascular techniques are often preferred for revascularization of lesions that involve the subclavian or the extracranial portion of the vertebral arteries.

Subclavian and vertebral bypass. Bypass surgery for vertebrobasilar insufficiency has become exceptional, given the advancements in endovascular technology. Still, bypass procedures remain a proven treatment option for vertebrobasilar insufficiency, as seen with vertebral artery occlusion or subclavian steal syndrome.

“Subclavian steal” is defined as a reversal of vertebral arterial flow. Duplex ultrasound is the first noninvasive test of choice for evaluating subclavian steal syndrome. Additional noninvasive tests, including MR angiography and CT angiography, can be used to diagnose an abnormality found on duplex ultrasound.

For patients with symptomatic subclavian steal syndrome, digital subtraction angiography with endovascular balloon dilatation with or without stent placement has become the first-line treatment because of its minimally invasive nature. Subclavian artery-to-carotid artery transposition or carotid artery-to-subclavian artery bypass remain proven alternatives, particularly in cases where the lesion cannot be crossed endovascularly (30). Subclavian and vertebral bypass surgical procedures commonly utilize the occipital artery, which is anastomosed to the extradural vertebral artery, the posterior inferior cerebellar artery, or the posterior cerebral artery branch, depending on the patient’s site of steno-occlusive disease (61; 63; 111). Endarterectomy of the vertebral artery has also been described, but this procedure is no longer used in routine practice, given the availability of endovascular angioplasty and stenting options.

Subclavian and vertebral artery angioplasty and stenting. Although the application of percutaneous transluminal angioplasty for the management of subclavian artery steno-occlusive lesions dates back to the 1980s (09; 83; 114), there remains an ongoing debate in the literature regarding angioplasty alone versus angioplasty with stenting, without any clear settlement based on the existing information (68; 03). Overall, there are probably lesions that can effectively be treated by angioplasty alone, but maintaining patency in more complex or resilient lesions likely requires stent placement. This seems particularly true in patients with occluded subclavian arteries, many of whom present with symptoms of neurologic (ie, vertebrobasilar) or cardiac (ie, internal mammary artery-coronary) steal (82; 51; 102).

Subclavian artery stenting basics

(a) Severe stenosis of the proximal left subclavian artery. (b) Magnified view demonstrating deployed stent and correction of stenosis. (Contributed by Dr. Tanya Singh and Dr. Pui Man Rosalind Lai.)

Lesions of the vertebral artery are prevalent, and a vertebral artery stenosis that causes 50% or more diameter reduction carries a stroke risk similar to that for carotid pathology (90; 34). Stroke risk is highest during the weeks that follow the index event (ie, acute ischemic stroke or transient ischemic attack) (59). Reports on vertebral artery angioplasty and stenting date back to the late 1990s (21; 80). Despite multiple reports of low rates of periprocedural complications and high efficiency in addressing refractory vertebrobasilar insufficiency in particular (112), there remains ongoing skepticism about the effectiveness of the technique and lack of randomized clinical trials to demonstrate improved outcomes compared to medical therapy alone (33; 81; 120). Also, in-stent restenosis remains definitively a risk, even if the severity of restenosis is often not sufficient to require additional intervention, and technological advances (eg, drug-eluting stents and balloons) are likely to continue to lower its incidence (94; 20). A case series from our center outlines the safe use of a drug-eluting, balloon-expandable Resolute Onyx™ coronary stent (Medtronic) as a unique technique to address vertebral artery ostial stenosis in both symptomatic and asymptomatic patients (77).

Vertebral artery ostial stenting

(a) DSA, AP view, of the left subclavian artery with severe stenosis of the left vertebral artery ostium. (b) A guide wire is visualized crossing the stenosis in the vertebral artery. (c) Postprocedural angiogram following sten...

Nonatherosclerotic lesions of the extracranial vertebral artery are less frequent, the most pervasive being traumatic dissection, typically at the interface of the V1-V2 or V2-V3 segments. As in the carotid territory, most dissections heal spontaneously without the need for intervention. However, there remains a subset of patients whose symptoms prove refractory to medical treatment or whose lesions cause flow compromise in the context of suboptimal contralateral collateral support, and these patients should definitively be considered for intervention. Stenting of extracranial vertebral artery dissections has been shown to be safe and effective, although the existing literature remains scarce (97; 31; 32; 28; 50).

Intracranial atherosclerosis

Intracranial atherosclerotic disease is the most common cause of acute ischemic stroke worldwide, and approximately 50,000 to 100,000 patients per year in the United States suffer from acute ischemic stroke due to intracranial atherosclerotic lesions (67). Its prevalence approximates 13% to 15% in the overall population and is even higher in African-Americans, Japanese, Chinese, and Hispanics, possibly due to a disproportionate prevalence of uncontrolled risk factors, such as arterial hypertension, in these populations (73; 110; 43; 118). Intracranial atherosclerosis carries considerable risk for acute ischemic stroke following any index event, irrespective of any chosen medical therapy. In fact, in two prospective randomized studies of stenting versus aggressive medical therapy (ie, SAMMPRIS and VISSIT), the patients in the medical groups still accrued acute ischemic stroke rates of approximately 5% to 9% during the first 30 days following randomization, and rates of 9% to 12% during the first year of follow-up (26; 25; 39; 123).

Unlike internal carotid artery or vertebral artery lesions, there is considerable variability among intracranial atherosclerotic lesions, particularly in relation to their location and relationship to other intracranial arteries.

Intracranial arterial segment types

The various segments of the intracranial internal carotid artery are illustrated, emphasizing the surrounding microenvironment, their presence proximal or distal to the Circle of Willis, and the presence of branching. Note the ...

Intracranial atherosclerosis lesions can be differentiated based on three attributes:

	Arterial wall morphology and its microenvironment. The wall of the first-order cerebral arteries (ie, internal carotid artery and vertebral artery) undergoes physical changes as the vessel traverses different spaces: progressive loss of the external lamina elastica, thinning of the tunica media, and variation in transmural pressures due to different surrounding tissues. As the vessel courses through the subarachnoid space, its wall continues to change, becoming increasingly thin and, hence, vulnerable to rupture (eg, iatrogenic subarachnoid hemorrhage from wire perforation during endovascular catheterization maneuvers).
	Relationship to major collateral vessels. Lesions located in arterial segments proximal to the Circle of Willis (eg, carotid bifurcation stenosis or occlusions) are not as likely to produce downstream hemodynamic compromise as those located distal to the communicating arteries (eg, thromboembolic occlusion of the middle cerebral artery). Although arterial territories distal to the Circle of Willis can still receive collateral support from leptomeningeal arterioles, this system is somewhat less predictable, particularly in the elderly with long-standing arterial hypertension.
	Presence of in situ collateral branches. The presence of collateral branches lends itself to these small vessels becoming embedded by the intracranial atherosclerosis lesion and, therefore, vulnerable to acute closure with subsequent ischemic stroke (eg, perforator occlusion due to either progression of an atherosclerotic lesion or during angioplasty or stenting).

Accordingly, not all intracranial atherosclerosis lesions are equivalent in terms of risk (both natural and procedural) and optimal therapeutic approach (ie, either medical or interventional).

Determinants of ischemia risk in cerebrovascular lesions

The major attributes that determine the degree of ischemic risk inherent to any cerebrovascular lesion are depicted in this artistic rendition. Hemodynamic Impact: As the vessel lumen decreases, the flow becomes progressively d...

Lack of discrimination between different types of intracranial atherosclerosis lesions potentially explains unsuccessful outcomes of certain clinical trials (ie, SAMMPRIS and VISSIT) (26; 39; 123), and granular differences in the morphology of intracranial atherosclerosis lesions have been shown to considerably influence the outcomes of percutaneous transluminal angioplasty and stenting (Table 2) (87; 88; 89).

Before 2011, more than 80 reports in the literature suggested that percutaneous transluminal angioplasty and stenting could be applied to the treatment of intracranial atherosclerosis lesions with reasonable safety, although there were concerns about high restenosis rates and uncertainty about efficacy (87; 88; 89; 36; 45; 46; 124; 108; 119). The results of two pivotal subsequent studies, SAMMPRIS and VISSIT, changed the prevailing enthusiasm for stenting of intracranial atherosclerosis lesions almost overnight (26; 39; 123). Both studies were stopped prematurely due to the results of interim analyses that uncovered 30-day stroke and death rates that were significantly higher in the patients treated endovascularly (ie, 14.7% and 29.3%, respectively) than in the medical treatment groups (ie, 5.8% and 9.4%, respectively). Interestingly, the stroke rates for the medically treated patients at 1-year follow-up were 12.2% and 15.1%, respectively, underscoring the seriousness of this condition. Both studies have been the subject of criticism, discussions, and controversy, with additional series continuing to appear in the literature in an attempt to elucidate select patient populations who may be considered for this therapy (107; 98; 22; Derdeyn 2015; 64). Despite these criticisms, the current American Heart Association guidelines for secondary stroke prevention due to a recent stroke or transient ischemic attack secondary to severe stenosis (70% to 99%) of an intracranial artery, 90-day dual antiplatelet therapy is the first-line treatment (72). However, the management guidelines for patients who have recurrent transient ischemic attacks or strokes despite dual antiplatelet therapy are less clear. Endovascular treatment may be considered in these patients or in select patients with hemodynamic compromise who suffer from recurrent stroke. Future studies are needed to determine the management of patients with recurrent stroke due to intracranial atherosclerotic disease and which patient population would maximally benefit from endovascular or surgical revascularization of intracranial atherosclerotic disease (42).

Table 2. Effect of Intracranial Artery Lesion Type on Outcomes of Percutaneous Transluminal Angioplasty and Stenting

Intracranial artery lesion	Attribute	Finding	Success	Restenosis
Type A	Extension	Discrete	90%	0%
	Length	< 5 mm
	Stenosis (ø)	70% to 90%
	Occlusion
	Accessibility	Not readily accessible. Straight
	Contour	Smooth
	Calcification	None
	Branch involvement	None
	Thrombus	None
Type B	Extension	Tubular	77%	31%
	Length	5 to 10 mm
	Stenosis	90% or greater
	Occlusion	Near
	Accessibility	Tortuous and angulated (45º to 90º)
	Contour	Irregular
	Calcification	Moderate
	Branch involvement	Yes. Protectable
	Thrombus	Possible
Type C	Extension	Diffuse	67%	67%
	Length	Greater than 10 mm
	Stenosis	Occlusion
	Occlusion	Yes
	Accessibility	Tortuous and angulated (greater than 90º)
	Contour	None
	Calcification	Severe
	Branch involvement	Yes. Not protectable
	Thrombus	Yes
Adapted from: (88; 89; 87).

Practice guidelines for intracranial atherosclerosis. The American Academy of Neurology Practice Advisory for preventing stroke in patients with symptomatic large-artery intracranial atherosclerosis recommends medical management to reduce the risk of recurrent stroke or death (115). Effective management options include antithrombotics, dyslipidemic agents, and lifestyle modification. Angioplasty or stenting and surgical bypass are not recommended as the first-line treatment for symptomatic intracranial atherosclerotic disease. The optimal stroke prevention for patients with recurrent strokes despite maximal medical therapy remains unknown.

Moyamoya disease

Moyamoya disease is a rare, progressive cerebrovascular disease defined by a progressive steno-occlusion of unknown etiology that affects the bilateral supraclinoid internal carotid artery and often involves the proximal anterior and middle cerebral arteries as well. The name “moyamoya” means “puff of smoke” in Japanese and describes the look of the tangle of tiny vessels formed in the basal ganglia to compensate for the blockage. Moyamoya disease was first described in Japan and is found in individuals worldwide; its incidence is higher in Asian countries than in Europe or North America. The disease primarily affects children, but it can also occur in adults. In children, the first symptom of moyamoya disease is often stroke or recurrent transient ischemic attacks (commonly referred to as “mini-strokes”), frequently accompanied by muscular weakness or paralysis affecting one side of the body. Adults may also experience these symptoms that arise from blocked arteries but more often experience a hemorrhagic stroke due to bleeding into the brain. Other symptoms of moyamoya disease include headaches, seizures, disturbed consciousness, involuntary movements, and vision problems, as well as cognitive or sensory impairment. Although most patients with moyamoya disease experience recurrent ischemic or hemorrhagic stroke, a subpopulation may also suffer from chronic hypoperfusion syndromes.

Moyamoya disease is a progressive cerebrovascular disorder that can be classified into six stages, each with typical angiographic findings, according to the Suzuki classification (113).

	Stage 1: Narrowing of the carotid arteries.
	Stage 2: Initial appearance of basal moyamoya with dilatation of all main cerebral arteries.
	Stage 3: Intensification of moyamoya vessels together with a reduction of flow in the middle and anterior cerebral arteries.
	Stage 4: Minimization of moyamoya vessels; the proximal portions of the posterior cerebral arteries become involved.
	Stage 5: Reduction of moyamoya vessels and absence of all main cerebral arteries.
	Stage 6: Disappearance of moyamoya vessels; the cerebral circulation is supplied only by the external carotid system.

In addition to moyamoya disease, moyamoya-like vascular changes are seen in association with radiotherapy to the head or neck (particularly radiotherapy for optic gliomas, craniopharyngiomas, and pituitary tumors) as well as with other conditions that include Down syndrome, neurofibromatosis type 1 (with or without tumors of the hypothalamic-optic pathway), and sickle cell disease.

Medical therapy for moyamoya disease includes single antiplatelet medication; the most often used is aspirin, 81 to 325 mg daily. Still, many patients will experience mental decline and multiple strokes because of the progressive narrowing of arteries. Therefore, cerebral blood flow augmentation surgery is often performed. Options for cerebral revascularization include direct EC-IC bypass (eg, superficial temporal artery-to-middle cerebral artery [STA-MCA] bypass) as well as indirect bypass techniques (eg, encephaloduroarteriosynangiosis, encephalomyosynangiosis, or omental transposition). Although many surgeons prefer direct bypass techniques in adult patients (to afford immediate improvement in cerebral hemodynamics), indirect methods remain popular, particularly in children and juvenile patients in whom they promote a robust extracranial-intracranial collateralization over a period of months to years.

Moyamoya disease angiographic appearance

A patient in the second decade of life presented with left upper extremity sensory changes and was found to have moyamoya disease. A cerebral catheter angiogram was performed. Anteroposterior (a) and lateral (b) views following...

Cerebrovascular bypass (ie, cerebral blood flow augmentation surgery). Cerebrovascular or intracerebral bypass collectively refers to a wide range of microsurgical techniques used to improve blood flow and oxygenation to the distal cerebral vasculature. These methods include direct (eg, anastomosis of an extracerebral artery to an intracerebral artery) and indirect (eg, apposition of an extracranial artery or vascularized tissue onto the pial surface) techniques. The former method affords immediate augmentation of hemodynamic flow; the latter method requires months to years for collateral vascular connections to develop. Various indirect bypass procedures include encephaloduroarteriosynangiosis (donor = superficial temporal artery), encephalomyosynangiosis (donor = temporalis muscle), and omental transposition (donor = vascularized abdominal tissue). In situ bypass involves an anastomosis between two intracerebral arteries; this is an uncommon procedure and is outside the scope of this article. Direct cerebral bypass can be further dichotomized into high-flow (eg, anastomosis of external carotid artery to an intracerebral artery using an interposition graft) and low-flow (eg, anastomosis of superficial temporal artery or occipital artery to middle cerebral artery). The superficial temporal artery-middle cerebral artery arterial graft is the most common of the direct procedures and is the focus of this article.

Direct superficial temporal artery to middle cerebral artery (STA-MCA) bypass surgery is typically performed under single antiplatelet therapy, the most often aspirin, 81 to 325 mg daily. Angiography provides information about the course and size of the donor (superficial temporal artery or occipital artery) and recipient (middle cerebral artery) arteries; the recipient artery should be at least 1 mm in diameter. Through the procedure, mean arterial pressure is maintained approximately 10% to 15% above baseline, and osmodiuresis is not used to avoid hypotension. Following exposure, under microscopic visualization, the recipient middle cerebral artery branch on the pial surface is dissected from its arachnoid attachments. Temporary clips are placed on the proximal and distal ends of the recipient artery, and the artery is opened sharply.

Extracranial-intracranial bypass: intraoperative images

(a) Donor superficial temporal artery (black arrow) is prepared for anastomosis to a recipient distal branch of the middle cerebral artery (white arrow) in a standard end-to-side fashion. (b) Completed end-to-side anastomosis (...

A temporary clip is placed on the proximal superficial temporal artery branch, the artery is transected distally and "fish-mouthed" to widen the orifice, and an end-to-side arterial anastomosis is completed. Micro-Doppler and indocyanine green videoangiography are used to verify patency of the graft. Postoperatively, the mean arterial pressure is maintained at baseline or slightly elevated, and aspirin is continued for life. Catheter angiography is performed at 6 to 12 months to verify graft patency.

Direct and indirect bypasses are currently standard for managing moyamoya disease that has failed conservative management. In the past, surgical revascularizations were often routinely performed for ischemic and atherosclerotic diseases. In 1985, the Extracranial/Intracranial Bypass Study Group published a prospective, international, randomized clinical trial to address the question of whether extracranial-to-intracranial (EC-IC) bypass in addition to optimal medical therapy was superior to best medical therapy alone in patients with recently-symptomatic extra- or intracranial athero-occlusive disease (Group EIBS 1985). After an average follow-up period of 55.8 months (and despite an excellent graft patency rate of 96%), the investigators found no surgical benefit for bypass surgery as compared to medical management alone (14% increase in relative risk of fatal and nonfatal stroke in the surgical group as compared to the medical group). Further, higher rates of major perioperative ischemic strokes were seen in the surgical group (4.5% vs 1.3%). Outcomes were particularly poor in patients with middle cerebral artery stenosis or occlusion and those with ongoing symptoms. This study was criticized for the lack of hemodynamic criteria used to select patients at particularly high risk of stroke and, therefore, likely to derive the most benefit from surgery. This critical issue was subsequently addressed in the Carotid Occlusion Surgery Study (COSS) (95). The COSS was a prospective, randomized, blinded-adjudicated trial designed to address the question of whether STA-MCA bypass (in addition to best medical therapy) reduced the 2-year risk of ipsilateral ischemic stroke as compared to optimal medical therapy alone. The trial enrolled patients who had recently suffered from symptomatic extracranial internal carotid artery occlusion and who had documented hemodynamic cerebral ischemia (ie, increased oxygen extraction fraction on positron emission tomography). Despite high graft patency rates (98%), the authors found no benefit for surgery (2-year ipsilateral stroke risk = 21% in the surgical group vs. 22.7% in the medical group; p = 0.8) and a higher rate of perioperative stroke in the surgical group (14.4% vs. 2%, respectively; 95% CI 4.9% to 19.9%). However, a follow-up report detailing the surgical results of COSS and excluding the patients who experienced perioperative strokes (within 30 days of surgery) revealed improved cerebral hemodynamics and lower rates of recurrent ipsilateral ischemic strokes in the surgical group as compared to the medical group (9% vs. 22.7%, respectively, at 2 years) (56). These findings suggest that factors unrelated to the surgery (eg, hemodynamic fragility of the patients involved) were likely responsible for the high perioperative stroke rate in the surgical group (100; 99). The more recent Chinese Carotid and Middle Cerebral Artery Occlusion Surgery Study (CMOSS) again confirmed no benefit of direct bypass in patients with symptomatic internal carotid artery or middle cerebral artery occlusion with hemodynamic insufficiency on CT perfusion imaging (79). Taken together, the EC-IC bypass, COSS, and CMOSS trials ultimately provided Level I evidence for the lack of benefit of STA-MCA bypass in patients with recently symptomatic extra- or intracranial athero-occlusive disease.

Current practice guidelines for Moyamoya disease. The American Heart Association/American Stroke Association current (2023) guidelines recommend that in patients with moyamoya disease and a history of ischemic stroke or TIA, the use of antiplatelet therapy for the prevention of ischemic stroke or TIA may be reasonable (52). There are class 2a recommendations for surgical revascularization in adult patients with symptomatic moyamoya disease. Endovascular or surgical treatment should be considered for hemorrhagic aneurysms of moyamoya vessels.

Acute ischemic stroke

Intravenous thrombolysis using alteplase remains the first-line therapy for eligible patients with acute ischemic stroke, provided that treatment is initiated within 4.5 hours of clearly defined symptom onset. For the time being, eligible patients should receive intravenous alteplase without delay, even if subsequent mechanical thrombectomy is being considered.

Indications and evidence. The purpose of mechanical thrombectomy is to restore cerebral blood flow in an attempt to salvage ischemic brain tissue that is not already infarcted. Mechanical thrombectomy is indicated for selected patients with acute ischemic stroke due to large artery occlusion, regardless of whether they have received intravenous thrombolysis for the same ischemic stroke event.

There was a turning point for mechanical thrombectomy in 2015 when the aforementioned five multicenter, open-label randomized controlled trials (MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, and REVASCAT) unequivocally demonstrated that early intra-arterial treatment with second-generation mechanical thrombectomy devices in early time windows (defined as 6 hours from last seen well) is superior (defined as a significant difference in the 90-day modified Rankin Scale score) to standard treatment with intravenous thrombolysis alone for ischemic stroke caused by a documented proximal anterior circulation artery occlusion (10; 18; 53; 70; 104). The number needed to treat for one additional person to achieve functional independence in these trials ranged from 3 to 7.5, and mechanical thrombectomy was beneficial across a wide range of patient subgroups, including patients older than 80 years, patients with high initial stroke severity, and patients not receiving intravenous thrombolysis (54).

Mechanical thrombectomy has also been shown safe and effective in the later time windows (6 to 24 hours) and for “wake-up” stroke patients who have a clinical deficit that is disproportionately severe compared with the volume of infarction on advanced imaging studies (for details, see DAWN and DEFUSE 3 trial eligibility criteria) (04; 91). The evidence for the benefit of mechanical thrombectomy in large core infarcts remains unclear. In a meta-analysis of four randomized controlled trials, endovascular therapy had better functional outcomes measured by mRS score and a higher probability of survival than medical therapy in patients with large ischemic core volume; however, the endovascular intervention group also had higher rates of symptomatic hemorrhage (74).

Finally, mechanical thrombectomy may be a reasonable treatment option for patients with acute large artery occlusion in the posterior circulation, such as the basilar artery, the vertebral artery, or the posterior cerebral artery. Recent meta-analyses of four randomized controlled trials demonstrated that patients with basilar artery occlusion who underwent thrombectomy had an improved mortality rate and better functional status at 3 months than patients treated with medical management alone. However, the risk of symptomatic intracranial hemorrhage was also higher in the intervention group (01; 13).

Technique. First-generation stent retrievers, such as the Merci® Retriever (Concentric Medical) or the Penumbra System® devices (Penumbra, Inc.), may increase recanalization rates in selected patients, but their ability to improve functional outcomes in patients with acute large artery occlusion remains unproven (109; 14; 15). With second-generation stent retrievers, such as the Solitaire™ Flow Restoration Device (Medtronic) and the Trevo® Retriever (Stryker), significantly higher reperfusion rates and better patient outcomes were achieved (92; 106). These second-generation devices were used in the positive thrombectomy trials, MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, and REVASCAT (10; 18; 53; 70; 104). Catheter aspiration techniques, such as A Direct Aspiration First Pass Technique (ADAPT), employ a catheter to aspirate the thrombus as the first approach. ADAPT has revascularization rates and functional outcome benefits comparable to those of second-generation stent retrievers (85; 76; 116). The continued refinement of devices, such as third-generation stent retrievers (Solitaire X™ [Medtronic]) and catheters (Red® 72 [Penumbra] and Zoom Stroke Solution™ [Imperative Care]), allows for increased vessel navigability and clot retrieval.

The technical advancement that made this possible was the introduction of "stent retrievers," which are devices that can be deployed just like a self-expandable stent across the occluding particle but remain attached to a wire that allows the operator to pull them back into a guide catheter, thereby retrieving the embolic material.

Large artery occlusion treatment: basic thrombectomy

(a) Patient who presented with acute right hemiplegia, aphasia, and evidence of occlusion (thrombolysis in cerebral infarction grade = 0) of the left middle cerebral artery M1 branch (arrow). (b) Stent retrieval of the occludin...

These devices, now in their third generation of design, introduced elements of efficiency and speed to urgent revascularization (ie, rescue) and changed the landscape of care for acute ischemic stroke. The impact of thrombectomy is supported by the remarkable consistency and reproducibility of the results of the different studies, several of which were stopped following interim analyses due to the loss of equipoise derived from the magnitude of benefit observed in their endovascular treatment arms. There are obvious differences and similarities in the design of these studies, yet the weight of their results has shaped our current approach to these patients. In addition, more recent publications have continued to confirm the data outlined in Table 3, including the HERMES metanalysis, which consolidated the experience derived from the five studies considered pivotal (105).

Side effects and complications. Mechanical thrombectomy is not associated with increased rates of symptomatic intracranial hemorrhage or mortality. Reported complications include failure to achieve complete revascularization, new ischemic stroke in a different vascular territory (10), and access site hematoma and pseudoaneurysm formation (18; 53).

Table 3. Pivotal Randomized Studies Demonstrating the Benefit of Urgent Thrombectomy for Large Artery Occlusion

	MRCLEAN	SWIFT PRIME	EXTEND-IA	ESCAPE	REVASCAT	HERMES
Population selection
Patients (endo only)	233	98	35	165	103	634
Stroke severity (NIHSS)	≥ 2	≥ 8 & < 30	None	> 5	≥ 6	N/A
Last seen well (hours)	≤ 6	≤ 6	≤ 6	< 12	8
Collaterals (ASPECTS)	No	No	No	≥ 5	≥ 7
Penumbra imaging	No	Yes	Yes	Yes (")	No
Pre-stroke function (mRS)	≤ 2	≤ 1	< 2	≤ 2	≤ 1
Preceding intravenous-TPA	203 (87.1%)	98 (100%)	35 (100%)	120 (72.7%)	70 (68%)	526 (83%)
Procedural metrics
Door to puncture time (min) (*)	260	224	210	185	269	238
Groin – flow (min) (*)	NR	28	38	56	NR	48
TICI 2b+3	115 (58.7%)	73 (88%)	25 (86%)	113 (72.4%)	67 (66%)	390 (71%)
Outcome metrics
90-day mRS 0-2 (%)	32.6	60	71	53	43.7
Mortality	27 (11.6)	12 (12%)	3 (9%)	17 (10.4%)	19 (18.4%)	97 (15.3%)
Infarct volume (ml) (*)	49	32	105	NR	16.3	NR
Trial stopped early	No	Yes	Yes	Yes	Yes	N/A
Safety metrics
Remote embolism	20 (8.6%)	NR	2 (6%)	NR	5 (4.9%)	NR
Dissection	4 (1.7%)	NR	NR	1 (0.6%)	4 (3.9%)	NR
Wire perforation	2 (0.9%)	NR	1 (2.8%)	1 (0.6%)	5 (4.9%)	NR
Totals hemorrhages	NR	9 (9.1%)	NR	NR	29 (28%)	NR
Sx hemorrhages	18 (7.7%)	0 (0%)	0 (0%)	6 (3.5%)	7 (6.7%)	28 (4.4%)
HI1	1 (0.4%)	NR	NR	27 (16.4%)	NR	NR
HI2	1 (0.4%)	NR	NR	25 (15.2%)	NR	NR
PH1	0 (0%)	4 (4%)	4 (11%)	5 (3%)	NR	NR
PH2	14 (6.0%)	1 (1%)	NR	4 (2.4%)	NR	32 (5.1%)
SAH	2 (0.9%)	4 (4%)	NR	5 (3%)	5 (4.8%)	NR
ASPECT, A Direct Aspiration First Pass Technique; HI, hemorrhagic infarction; min, minutes; ml, milliliters; mRS, modified Rankin Scale (score); N/A, not applicable; NIHSS, National Institutes of Health Stroke Scale (score); NR, not reported; PH, parenchymal hemorrhage; SAH, subarachnoid hemorrhage; Sx, symptomatic; TICI, thrombolysis in cerebral infarction; TPA, tissue plasminogen activator; (*), median; ("), not systematically for inclusion

The shift from a strict "therapeutic time window" to a more individualized approach obeys the successful introduction of imaging techniques capable of identifying potentially salvageable (ie, ischemic but not infarcted, or "ischemic penumbra") brain tissue along the time continuum (06). Data from the studies that included CT or MR perfusion as intrinsic steps in their protocols (ie, SWIFT PRIME and EXTEND-IA) demonstrated that certain imaging patterns are associated with a greater chance of improvement following thrombectomy or to predict futility of intervention (18; 104; 86).

Endovascular rescue patient selection: perfusion scanning

(a) The "ideal" patient is one with a large mismatch between the ischemic core and the penumbra volume, particularly if the cerebral blood volume is maintained normal (i). Although this is the picture of the typical onset, as t...

Multiple trials, such as MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, and REVASCAT, demonstrated the superiority of mechanical thrombectomy over intravenous thrombectomy alone among patients with acute stroke when performed within 6 hours of symptom onset (10; 18; 53; 70; 104). Even if benefits of the intervention decline as the time since onset increases, a subset of patients remains in whom ischemic brain tissue remains salvageable in case of reperfusion. Herein, the DAWN and DEFUSE 3 trials demonstrated a 90-day functional outcome benefit of mechanical thrombectomy over standard therapy alone in patients with anterior circulation large artery occlusion and favorable perfusion imaging pattern in the 6- to 24-hour window after initial onset of symptoms (04; 05; 91).

The "ideal" imaging profile of a patient who is likely to benefit from thrombectomy for large artery occlusion is one with: (a) a much larger area of penumbra than ischemic "core" (ie, large mismatch), (b) a small area of ischemic "core," and (c) normal cerebral blood volume. The specifics of how this has translated into the clinical trials are displayed in Table 4.

Table 4. Perfusion Scanning Criteria That Defined the "Ideal" Candidates for Endovascular Rescue of Acute Ischemic Stroke Due to Large Artery Occlusion in Two Major Trials

Study	Core threshold	Core volume	Penumbra threshold	Penumbra volume	Mismatch ratio	Mismatch volume
SWIFT PRIME	NS	< 50 ml < 80 y	Tmax > 10 sec	≥ 15 ml	> 1.8	NS
		< 20 ml ≥ 80 y
EXTEND-IA	< 30%	< 70 ml	Tmax > 6 sec	NS	> 1.2	> 10 ml
ml, milliliters; NS, not studied; sec, seconds; Tmax, time-to-maximum; y, years in age

Practice guidelines for mechanical thrombectomy. The American Heart Association/American Stroke Guidelines 2019 Update recommends consideration of mechanical thrombectomy for patients within 0 to 6 hours from symptom onset if they meet the following criteria: pre-stroke mRS score of 0-1, large vessel occlusion of the internal carotid artery or M1 segment of the middle cerebral artery, age older than 18 years, NIHSS score greater than 6, ASPECTS score greater than 6, and treatment can be initiated (groin puncture) within 6 hours from symptom onset (96). Mechanical thrombectomy in the M2 or M3 portion of the middle cerebral artery may be considered in carefully selected patients.

For patients 6 to 24 hours from onset and those who have large vessel occlusion in the anterior circulation and meet other DAWN and DEFUSE 3 eligibility criteria (04; 91) (Table 5), mechanical thrombectomy should be considered.

Table 5. Selection Criteria for the DAWN and DEFUSE-3 Thrombectomy Trials

	DAWN	DEFUSE-3
Eligibility	6 to 24 hours	6 to 16 hours
Location of large vessel occlusion	Intracranial ICA or proximal MCA	Extra- or intracranial ICA or proximal MCA
Infarct volume	≤20 mL if age>80 ≤30 mL if age<80 and NIHSS score 10-20 ≤50 mL if age<80 and NIHSS score >20	≤70 mL
Mismatch volume	Not required	≥15 mL and a mismatch ratio of ≥1.8
ICA, internal carotid artery; MCA, middle cerebral artery; mL, milliliters; NIHSS, National Institutes of Health Stroke Scale

Media

References

01: Abdalkader M, Finitsis S, Li C, et al. Endovascular versus medical management of acute basilar artery occlusion: a systematic review and meta-analysis of the randomized controlled trials. J Stroke 2023;25(1):81-91. PMID 36746382
02: AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for vascular surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg 2022;75(1S):4S-22S. PMID 34153348
03: Ahmed AT, Mohammed K, Chehab M, et al. Comparing percutaneous transluminal angioplasty and stent placement for treatment of subclavian arterial occlusive disease: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2016;39(5):652-67. PMID 26630966
04: Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018a;378(8):708-18. PMID 29364767
05: Albers GW, Marks MP, Lansberg MG. Thrombectomy for stroke with selection by perfusion imaging. N Engl J Med 2018b;378(19):1849-50. PMID 29742373
06: Allmendinger AM, Tang ER, Lui YW, Spektor V. Imaging of stroke: Part 1, Perfusion CT--overview of imaging technique, interpretation pearls, and common pitfalls. AJR Am J Roentgenol 2012;198(1):52-62. PMID 22194479
07: Anonymous. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273(18):1421-8. PMID 7723155
08: Anonymous. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351(9113):1379-87. PMID 9593407
09: Bachman DM, Kim RM. Transluminal dilatation for subclavian steal syndrome. AJR Am J Roentgenol 1980;135(5):995-6. PMID 6778179
10: Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372(1):11-20. PMID 25517348
11: Blackshear JL, Cutlip DE, Roubin GS, et al. Myocardial infarction after carotid stenting and endarterectomy: results from the carotid revascularization endarterectomy versus stenting trial. Circulation 2011;123(22):2571-8. PMID 21606394
12: Bontinis V, Antonopoulos CN, Bontinis A, et al. A systematic review and meta-analysis of carotid artery stenting for the treatment of cervical carotid artery dissection. Eur J Vasc Endovasc Surg 2022;64(4):299-308. PMID 35961627
13: Bouslama M, Kuo CC, Monteiro A, et al. Mechanical thrombectomy versus medical management for acute basilar artery occlusions: a meta-analysis of randomized trials. Interv Neuroradiol 2023:15910199231157924. PMID 37005965
14: Brinjikji W, Rabinstein AA, Kallmes DF, Cloft HJ. Patient outcomes with endovascular embolectomy therapy for acute ischemic stroke: a study of the national inpatient sample: 2006 to 2008. Stroke 2011;42(6):1648-52. PMID 21493901
15: Broderick JP, Schroth G. What the SWIFT and TREVO II trials tell us about the role of endovascular therapy for acute stroke. Stroke 2013;44(6):1761-4. PMID 23686978
16: Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363(1):11-23. PMID 20505173
17: Brott TG, Howard G, Roubin GS, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med 2016;374(11):1021-31. PMID 26890472
18: Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372(11):1009-18. PMID 25671797
19: Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. Ann Neurol 2004;56(3):389-98. PMID 15349866
20: Chang JY, Park H, Kwon O, Han MK. Restenosis after stenting in symptomatic vertebral arterial orifice disease and considerations for better outcome. Interv Neuroradiol 2017;23(2):180-5. PMID 28304206
21: Chastain HD 2nd, Campbell MS, Iyer S, et al. Extracranial vertebral artery stent placement: in-hospital and follow-up results. J Neurosurg 1999;91(4):547-52. PMID 10507373
22: Chatterjee AR, Derdeyn CP. Stenting in intracranial stenosis: current controversies and future directions. Curr Atheroscler Rep 2015;17(8):48. PMID 26104430
23: Chen F, Ni YC. Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update. World J Radiol 2012;4(3):63-74. PMID 22468186
24: Chiari H. Ueber des verhalten des teilungswinkels der carotid communis bei der endarteritis chronica deformans. Verh Dtsch Path Ges 1905;9:326.
25: Chimowitz MI. Endovascular treatment for acute ischemic stroke--still unproven. N Engl J Med 2013;368(10):952-5. PMID 23394477
26: Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365(11):993-1003. PMID 21899409
27: Chou SN. Embolectomy of middle cerebral artery: report of a case. J Neurosurg 1963;20:161-3. PMID 14192086
28: Chupin AV, Kalinin AA, Lebedev DP, Maliutina ED, Zaĭtsev MV. [Stenting in vertebral artery dissection: an approach to management]. [Russian.] Angiol Sosud Khir 2008;14(2):59-63. PMID 19156052
29: Cilingiroglu M, Marmagkiolis K, Wholey MH. Carotid artery stenting update. Future Cardiol 2013;9(2):193-7. PMID 23463972
30: Cina CS, Safar HA, Laganà A, Arena G, Clase CM. Subclavian carotid transposition and bypass grafting: consecutive cohort study and systematic review. J Vasc Surg 2002;35(3):422-9. PMID 11877687
31: Cohen JE, Gomori JM, Umansky F. Endovascular management of spontaneous bilateral symptomatic vertebral artery dissections. AJNR Am J Neuroradiol 2003a;24(10):2052-6. PMID 14625232
32: Cohen JE, Gomori JM, Umansky F. Endovascular management of symptomatic vertebral artery dissection achieved using stent angioplasty and emboli protection device. Neurol Res 2003b;25(4):418-22. PMID 12870271
33: Compter A, Chaturvedi S. Vertebral artery stenosis: The hurdles of stenting are too high. Neurology 2017;89(12):1204-5. PMID 28835398
34: Compter A, van der Worp HB, Algra A, Kappelle LJ; Second Manifestations of ARTerial disease (SMART) Study Group. Prevalence and prognosis of asymptomatic vertebral artery origin stenosis in patients with clinically manifest arterial disease. Stroke 2011;42(10):2795-800. PMID 21852605
35: Conway SA, Bowling SM, Geyer JD, Potts DC, Clemons BL, Gomez CR. Quantitative magnetic resonance angiography of the cerebrovasculature in physiologic and pathologic states. J Neuroimaging 2008;18(1):34-7. PMID 18190493
36: Cruz-Flores S, Diamond AL. Angioplasty for intracranial artery stenosis. Cochrane Database Syst Rev 2006;(3):CD004133. PMID 16856032
37: de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41(6):1294-7. PMID 20431077
38: DeBakey ME. Successful carotid endarterectomy for cerebrovascular insufficiency. Nineteen-year follow-up. JAMA 1975;233(10):1083-5. PMID 1174155
39: Derdeyn CP, Fiorella D, Lynn MJ, et al. Intracranial stenting: SAMMPRIS. Stroke 2013;44(6 Suppl 1):S41-4. PMID 23709726
40: Diethrich EB, Gordon MH, Lopez-Galarza LA, Rodriguez-Lopez JA, Casses F. Intraluminal Palmaz stent implantation for treatment of recurrent carotid artery occlusive disease: a plan for the future. J Interv Cardiol 1995;8(3):213-8. PMID 10155231
41: Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technic and a preliminary report of its application. Circulation 1964;30:654-70. PMID 14226164
42: Elder TA, White TG, Woo HH, et al. Future of endovascular and surgical treatments of atherosclerotic intracranial stenosis. Stroke 2024;55(2):344-54. PMID 38252761
43: Feldmann E, Daneault N, Kwan E, et al. Chinese-white differences in the distribution of occlusive cerebrovascular disease. Neurology 1990;40(10):1541-5. PMID 2215945
44: Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994;44(6):1046-50. PMID 8208397
45: Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007;38(3):881-7. PMID 17290030
46: Fiorella D, Woo HH. Emerging endovascular therapies for symptomatic intracranial atherosclerotic disease. Stroke 2007;38(8):2391-6. PMID 17585085
47: Flaherty ML. Carotid artery stenosis as a cause of stroke. Neuroepidemiology 2013;40(1):36-41. PMID 23075828
48: Friedman SG. The first carotid endarterectomy. J Vasc Surg 2014;60(6):1703-8.e1-4. PMID 25238726
49: Gomez CR, Wadlington VR, Terry JB, Tulyapronchote R. Neuroendovascular rescue. Nonthrombolytic approach to acute brain ischemia. Crit Care Clin 1999;15(4):755-76. PMID 10569120
50: Gomez JD, Bravo-Rodriguez Fde A, Fernandez RO. [Vertebral artery pseudoaneurysm]. Neurologia 2009;24(9):816-7. PMID 21476229
51: Gonzalez A, Gil-Peralta A, González-Marcos JR, Mayol A. Angioplasty and stenting for total symptomatic atherosclerotic occlusion of the subclavian or innominate arteries. Cerebrovasc Dis 2002;13(2):107-13. PMID 11867884
52: Gonzalez NR, Amin-Hanjani S, Bang OY, et al. Adult moyamoya disease and syndrome: current perspectives and future directions: a scientific statement from the American Heart Association/American Stroke Association. Stroke 2023;54(10):e465-79. PMID 37609846
53: Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30. PMID 25671798
54: Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387(10029):1723-31. PMID 26898852
55: Group EIBS. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med 1985;313(19):1191-200. PMID 2865674
56: Grubb RL Jr, Powers WJ, Clarke WR, et al. Surgical results of the Carotid Occlusion Surgery Study. J Neurosurg 2013;118(1):25-33. PMID 23101451
57: Gruntzig A, Hopff H. [Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter (modification of the Dotter technique) (author's transl)]. Dtsch Med Wochenschr 1974;99(49):2502-11. PMID 4434847
58: Gulli G, Khan S, Markus HS. Vertebrobasilar stenosis predicts high early recurrent stroke risk in posterior circulation stroke and TIA. Stroke 2009;40(8):2732-7. PMID 19478210
59: Gulli G, Marquardt L, Rothwell PM, Markus HS. Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. Stroke 2013;44(3):598-604. PMID 23386676
60: Habersberger J, Brott TG, Roubin GS. Carotid artery stenting: a clinical update. Curr Opin Cardiol 2012;27(6):565-71. PMID 22941123
61: Hadley MN, Spetzler RF, Masferrer R, Martin NA, Carter LP. Occipital artery to extradural vertebral artery bypass procedure. Case report. J Neurosurg 1985;63(4):622-5. PMID 4032027
62: Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010;376(9746):1074-84. PMID 20870099
63: Hopkins LN, Martin NA, Hadley MN, Spetzler RF, Budny J, Carter LP. Vertebrobasilar insufficiency. Part 2. Microsurgical treatment of intracranial vertebrobasilar disease. J Neurosurg 1987;66(5):662-74. PMID 3553454
64: Housley SB, Vakharia K, Gong AD, et al. Extracranial-to-intracranial bypass for distal internal carotid artery and/or proximal middle cerebral artery steno-occlusive disease: a case series of clinical outcomes at a single, high-volume cerebrovascular center. Oper Neurosurg (Hagerstown) 2022;23(3):177-181. PMID 35972078
65: Howard VJ, Meschia JF, Lal BK, et al. Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. Int J Stroke 2017;12(7):770-8. PMID 28462683
66: Hunt JR. Hunt: the role of the carotid arteries: the role of the carotid arteries, in the causation of vascular lesions of the brain, with remarks on certain special features of the symptomatology. 1914. Am J Med Sci 2013;346(6):504-9. PMID 24263078
67: Hussain M, Datta N, Cheng Z, et al. Spanning from the West to East: an updated review on endovascular treatment of intracranial atherosclerotic disease. Aging Dis 2017;8(2):196-202. PMID 28400985
68: Iared W, Mourão JE, Puchnick A, Soma F, Shigueoka DC. Angioplasty versus stenting for subclavian artery stenosis. Cochrane Database Syst Rev 2014;(5):CD008461. PMID 24833157
69: Jalbert JJ, Nguyen LL, Gerhard-Herman MD, et al. Comparative effectiveness of carotid artery stenting versus carotid endarterectomy among medicare beneficiaries. Circ Cardiovasc Qual Outcomes 2016;9(3):275-85. PMID 27116974
70: Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372(24):2296-306. PMID 25882510
71: Kashyap VS, So KL, Schneider PA, et al. One-year outcomes after transcarotid artery revascularization (TCAR) in the ROADSTER 2 trial. J Vasc Surg 2022;76(2):466-73.e1. PMID 35381327
72: Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45(7):2160-236. PMID 24788967
73: Kieffer SA, Takeya Y, Resch JA, Amplatz K. Racial differences in cerebrovascular disease. Angiographic evaluation of Japanese and American populations. Am J Roentgenol Radium Ther Nucl Med 1967;101(1):94-9. PMID 6037345
74: Kobeissi H, Adusumilli G, Ghozy S, et al. Endovascular thrombectomy for ischemic stroke with large core volume: an updated, post-TESLA systematic review and meta-analysis of the randomized trials. Interv Neuroradiol 2023:15910199231185738. PMID 37376869
75: Kwolek CJ, Jaff MR, Leal JI, et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg 2015;62(5):1227-34. PMID 26506270
76: Lapergue B, Blanc R, Gory B, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: The ASTER Randomized Clinical Trial. JAMA 2017;318(5):443-52. PMID 28763550
77: Lim J, Baig AA, Aguirre AO, et al. Use of drug-eluting, balloon-expandable resolute onyx coronary stent as a novel treatment strategy for vertebral artery ostial stenosis: case series. Interv Neuroradiol 2022:15910199221138138. PMID 36357368
78: Lui YW, Tang ER, Allmendinger AM, Spektor V. Evaluation of CT perfusion in the setting of cerebral ischemia: patterns and pitfalls. AJNR Am J Neuroradiol 2010;31(9):1552-63. PMID 20190208
79: Ma Y, Wang T, Wang H, et al. Extracranial-intracranial bypass and risk of stroke and death in patients with symptomatic artery occlusion: the CMOSS randomized clinical trial. JAMA 2023;330(8):704-14. PMID 37606672
80: Malek AM, Higashida RT, Phatouros CC, et al. Treatment of posterior circulation ischemia with extracranial percutaneous balloon angioplasty and stent placement. Stroke 1999;30(10):2073-85. PMID 10512910
81: Markus HS, Larsson SC, Kuker W, et al. Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. Neurology 2017;89(12):1229-36. PMID 28835400
82: Martinez R, Rodriguez-Lopez J, Torruella L, Ray L, Lopez-Galarza L, Diethrich EB. Stenting for occlusion of the subclavian arteries. Technical aspects and follow-up results. Tex Heart Inst J 1997;24(1):23-7. PMID 9068135
83: Mathias K, Staiger J, Thron A, Spillner G, Heiss HW, Konrad-Graf S. [Percutaneous transluminal dilatation of the subclavian artery (author's transl)]. Dtsch Med Wochenschr 1980;105(1):16-8. PMID 7351164
84: Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991;266(23):3289-94. PMID 1960828
85: Mocco J, Zaidat OO, von Kummer R, et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke 2016;47(9):2331-8. PMID 27486173
86: Mokin M, Levy EI, Saver JL, et al. Predictive value of RAPID assessed perfusion thresholds on final infarct volume in SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment). Stroke 2017;48(4):932-8. PMID 28283606
87: Mori T, Kazita K, Chokyu K, Mima T, Mori K. Short-term arteriographic and clinical outcome after cerebral angioplasty and stenting for intracranial vertebrobasilar and carotid atherosclerotic occlusive disease. AJNR Am J Neuroradiol 2000;21(2):249-54. PMID 10696004
88: Mori T, Kazita K, Chokyu K, Mori K. Stenting treatment for intra- and extra-cranial atherosclerotic diseases. Interv Neuroradiol 1999a;5 Suppl 1:51-3. PMID 20670539
89: Mori T, Kazita K, Mori K. Cerebral angioplasty and stenting for intracranial vertebral atherosclerotic stenosis. AJNR Am J Neuroradiol 1999b;20(5):787-9. PMID 10369347
90: Moufarrij NA, Little JR, Furlan AJ, Williams G, Marzewski DJ. Vertebral artery stenosis: long-term follow-up. Stroke 1984;15(2):260-3. PMID 6701934
91: Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378(1):11-21. PMID 29129157
92: Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380(9849):1231-40. PMID 22932714
93: North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJ, Taylor DW, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325(7):445-53. PMID 1852179
94: Ogilvy CS, Yang X, Natarajan SK, et al. Restenosis rates following vertebral artery origin stenting: does stent type make a difference? J Invasive Cardiol 2010;22(3):119-24. PMID 20197579
95: Powers WJ, Clarke WR, Grubb RL Jr, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011;306(18):1983-92. PMID 22068990
96: Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019; 50(12):e344-418. PMID 31662037
97: Price RF, Sellar R, Leung C, O'Sullivan MJ. Traumatic vertebral arterial dissection and vertebrobasilar arterial thrombosis successfully treated with endovascular thrombolysis and stenting. AJNR Am J Neuroradiol 1998;19(9):1677-80. PMID 9802490
98: Qureshi AI, Al-Senani FM, Husain S, et al. Intracranial angioplasty and stent placement after stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial: present state and future considerations. J Neuroimaging 2012;22(1):1-13. PMID 22250951
99: Reynolds MR, Derdeyn CP, Grubb RL Jr, Powers WJ, Zipfel GJ. Extracranial-intracranial bypass for ischemic cerebrovascular disease: what have we learned from the Carotid Occlusion Surgery Study? Neurosurg Focus 2014;36(1):E9. PMID 24380486
100: Reynolds MR, Grubb RL Jr, Clarke WR, et al. Investigating the mechanisms of perioperative ischemic stroke in the Carotid Occlusion Surgery Study. J Neurosurg 2013;119(4):988-95. PMID 23909253
101: Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361(9352):107-16. PMID 12531577
102: Sakai C, Sakai N, Kuroiwa T, et al. Stenting for chronic total occlusion of the proximal subclavian artery. Interv Neuroradiol 2007;13 Suppl 1:135-40. PMID 20566091
103: Sardar P, Chatterjee S, Aronow HD, et al. Carotid artery stenting versus endarterectomy for stroke prevention: a meta-analysis of clinical trials. J Am Coll Cardiol 2017;69(18):2266-75. PMID 28473130
104: Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372(24):2285-95. PMID 25882376
105: Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 2016;316(12):1279-88. PMID 27673305
106: Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380(9849):1241-9. PMID 22932715
107: Siddiq F, Chaudhry SA, Khatri R, et al. Rate of postprocedural stroke and death in SAMMPRIS trial-eligible patients treated with intracranial angioplasty and/or stent placement in practice. Neurosurgery 2012;71(1):68-73. PMID 22382209
108: Siddiq F, Memon MZ, Vazquez G, Safdar A, Qureshi AI. Comparison between primary angioplasty and stent placement for symptomatic intracranial atherosclerotic disease: meta-analysis of case series. Neurosurgery 2009;65(6):1024-34. PMID 19934961
109: Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36(7):1432-38. PMID 15961709
110: Solberg LA, McGarry PA. Cerebral atherosclerosis in Negroes and Caucasians. Atherosclerosis 1972;16(2):141-54. PMID 4634809
111: Spetzler RF, Hadley MN, Martin NA, Hopkins LN, Carter LP, Budny J. Vertebrobasilar insufficiency. Part 1: Microsurgical treatment of extracranial vertebrobasilar disease. J Neurosurg 1987;66(5):648-61. PMID 3553453
112: Stayman AN, Nogueira RG, Gupta R. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke 2011;42(8):2212-6. PMID 21700936
113: Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969;20(3):288-99. PMID 5775283
114: Theron J, Courtheoux P, Henriet JP, Pelouze G, Derlon JM, Maiza D. Angioplasty of supraaortic arteries. J Neuroradiol 1984;11(3):187-200. PMID 6239913
115: Turan TN, Zaidat OO, Gronseth GS, et al. Stroke prevention in symptomatic large artery intracranial atherosclerosis practice advisory: report of the AAN Guideline Subcommittee. Neurology 2022;98(12):486-98. PMID 35314513
116: Turk AS, 3rd, Siddiqui A, Fifi JT, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet 2019;393(10175):998-1008. PMID 30860055
117: Welch K. Excision of occlusive lesions of the middle cerebral artery. J Neurosurg 1956;13(1):73-80. PMID 13286728
118: White H, Boden-Albala B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005;111(10):1327-31. PMID 15769776
119: Wolfe TJ, Fitzsimmons BF, Hussain SI, Lynch JR, Zaidat OO. Long term clinical and angiographic outcomes with the Wingspan stent for treatment of symptomatic 50-99% intracranial atherosclerosis: single center experience in 51 cases. J Neurointerv Surg 2009;1(1):40-3. PMID 21994104
120: Xu R, Zhang X, Liu S et al. Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis. Cochrane Database Syst Rev 2022;5(5):CD013692. PMID 35579383
121: Yasaka M, Read SJ, O'Keefe GJ, et al. Positron emission tomography in ischaemic stroke: cerebral perfusion and metabolism after stroke onset. J Clin Neurosci 1998;5(4):413-6. PMID 18639064
122: Yasargil MG. [Possibilities and limitations of vascular surgery of the central nervous system]. Bull Schweiz Akad Med Wiss 1969;24(5):487-93. PMID 5376063
123: Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015;313(12):1240-8. PMID 25803346
124: Zaidat OO, Wolfe T, Hussain SI, et al. Interventional acute ischemic stroke therapy with intracranial self-expanding stent. Stroke 2008;39(8):2392-5. PMID 18556584
125: Zeumer H, Hacke W, Ringelstein EB. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR Am J Neuroradiol 1983a;4(3):401-4. PMID 6410756
126: Zeumer H, Ringelstein EB, Hassel M, Poeck K. [Local fibrinolysis therapy in subtotal stenosis of the median cerebral artery]. Dtsch Med Wochenschr 1983b;108(28-9):1103-5. PMID 6861655

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Pui Man Rosalind Lai MD

Dr. Lai of Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, has no relevant financial relationships to disclose.
See Profile
Tanya Singh MD

Dr. Singh of University at Buffalo has no relevant financial relationships to disclose.
See Profile

Editor

Steven R Levine MD

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.
See Profile

Former Authors

Eric S Nussbaum MD
John Sinclair MD
Steven D Chang MD
Daniel M Heiferman MD
Matthew R Reynolds MD PhD
Joseph C Serrone MD
Jose Biller MD
Camilo R Gomez MD
Daniel Zumofen

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: Male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none

ICD & OMIM codes

ICD-10: Acute cerebrovascular insufficiency NOS: I67.8

Cerebral atherosclerosis: I67.2

Cerebral infarction due to cerebral venous thrombosis, nonpyogenic: I63.6

Moyamoya disease: I67.5

Occlusion and stenosis of carotid artery: I65.2

Occlusion and stenosis of multiple and bilateral precerebral arteries: I65.3

Occlusion and stenosis of other precerebral artery: I65.8

Occlusion and stenosis of unspecified cerebral artery: I66.9

Other transient cerebral ischemic attacks and related syndromes: G45.8

Transient cerebral ischemic attack, unspecified: G45.9
ICD-11: Asymptomatic stenosis of intracranial or extracranial artery: BD55

Cerebral ischaemic stroke due to unspecified occlusion or stenosis of extracranial large artery: 8B11.50

Cerebral ischaemic stroke of unknown cause: 8B11.5

Cerebral venous thrombosis: 8B22.1

Moyamoya syndrome: 8B22.B

Other specified cerebrovascular disease: 8B22.Y

Other specified transient ischaemic attack: 8B10.Y

Transient ischaemic attack: 8B10
OMIM: Moyamoya disease: %252350

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cerebral revascularization: surgical and endovascular approaches

Associated Disorders

Carotid atherosclerosis
Cerebrovascular disease
Coronary artery disease
Diabetes
Extracranial carotid artery occlusive disease
- Intracranial atherothrombosis
- Intracranial occlusive disease
- Myocardial infarction
- Peripheral vascular disease

Also Relevant

Basilar artery stroke
Endovascular treatment of acute ischemic stroke
Carotid bruit
Cerebral embolism
Interventional neuroradiology for neurologic disorders
- Intracranial atherosclerosis
- Ischemic stroke
- Moyamoya disease
- Primary prevention of stroke
- Secondary stroke prevention
- Spontaneous carotid and vertebral artery dissection
- Subclavian steal
- Stroke therapy

Clinical Categories

Stroke & Vascular Disorders

Cerebral revascularization: surgical and endovascular approaches …

Cerebral revascularization: surgical and endovascular approaches

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Table 1. Attributes That Determine the Risk Of Arterial Lesions To Induce Cerebral Ischemia

Extracranial atherosclerotic diseases

Carotid stenosis

Nonatherosclerotic lesions

Extracranial vertebrobasilar circulation

Intracranial atherosclerosis

Table 2. Effect of Intracranial Artery Lesion Type on Outcomes of Percutaneous Transluminal Angioplasty and Stenting

Moyamoya disease

Acute ischemic stroke

Table 3. Pivotal Randomized Studies Demonstrating the Benefit of Urgent Thrombectomy for Large Artery Occlusion

Table 4. Perfusion Scanning Criteria That Defined the "Ideal" Candidates for Endovascular Rescue of Acute Ischemic Stroke Due to Large Artery Occlusion in Two Major Trials

Table 5. Selection Criteria for the DAWN and DEFUSE-3 Thrombectomy Trials

Future directions

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Vein of Galen malformations

Patent foramen ovale

Neuroimaging in acute stroke

Atrial myxoma

Anterior cerebral artery stroke syndromes

Hemorrhagic transformation of ischemic stroke

Intracerebral hemorrhage due to thrombolytic therapy

White matter abnormalities in the brain

Cerebral revascularization: surgical and endovascular approaches

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Table 1. Attributes That Determine the Risk Of Arterial Lesions To Induce Cerebral Ischemia

Extracranial atherosclerotic diseases

Carotid stenosis

Nonatherosclerotic lesions

Extracranial vertebrobasilar circulation

Intracranial atherosclerosis

Table 2. Effect of Intracranial Artery Lesion Type on Outcomes of Percutaneous Transluminal Angioplasty and Stenting

Moyamoya disease

Acute ischemic stroke

Table 3. Pivotal Randomized Studies Demonstrating the Benefit of Urgent Thrombectomy for Large Artery Occlusion

Table 4. Perfusion Scanning Criteria That Defined the "Ideal" Candidates for Endovascular Rescue of Acute Ischemic Stroke Due to Large Artery Occlusion in Two Major Trials

Table 5. Selection Criteria for the DAWN and DEFUSE-3 Thrombectomy Trials

Future directions

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vein of Galen malformations

Patent foramen ovale

Neuroimaging in acute stroke

Atrial myxoma

Anterior cerebral artery stroke syndromes

Hemorrhagic transformation of ischemic stroke

Intracerebral hemorrhage due to thrombolytic therapy

White matter abnormalities in the brain

This is an article preview.
Start a Free Account
to access the full version.